NASDAQ: ZTEKZentek Ltd Stock
$0.87-0.01 (-1.14%)
Updated Sep 13, 2024
ZTEK Price
$0.87
Fair Value Price
$0.01
Market Cap
$88.07M
52 Week Low
$0.80
52 Week High
$1.59
P/E
-10.12x
P/B
6.67x
P/S
4,186.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.40k
Earnings
-$8.10M
Gross Margin
-909.6%
Operating Margin
-31,135.11%
Profit Margin
-31,443.5%
Debt to Equity
0.14
Operating Cash Flow
-$6M
Beta
0.72
Next Earnings
Oct 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ZTEK Overview
Zentek Limited researches and develops graphene and related nanomaterials. It owns 100% interest in the Albany Graphite Project located in Northern Ontario, Canada. The company develops antimicrobial coating and surgical masks, HVAC filters, and personal protective equipment. It is also developing synthesized graphene, graphene oxide, and graphene quantum dots. The company was known as ZEN Graphene Solutions Ltd. until 2021/10. Zentek was founded in 2008 and is headquartered in Thunder Bay, Canada.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZTEK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZTEK ($0.87) is overvalued by 6,444.23% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ZTEK ($0.87) is not significantly undervalued (6,444.23%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ZTEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ZTEK due diligence checks available for Premium users.
Be the first to know about important ZTEK news, forecast changes, insider trades & much more!
ZTEK News
Valuation
ZTEK fair value
Fair Value of ZTEK stock based on Discounted Cash Flow (DCF)
Price
$0.87
Fair Value
$0.01
Overvalued by
6,444.23%
ZTEK ($0.87) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ZTEK ($0.87) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ZTEK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ZTEK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.12x
Industry
-60.63x
Market
23.21x
ZTEK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.67x
Industry
4.03x
ZTEK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZTEK's financial health
Profit margin
Revenue
$4.0k
Net Income
-$1.9M
Profit Margin
-46,514.6%
ZTEK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ZTEK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.2M
Liabilities
$1.9M
Debt to equity
0.14
ZTEK's short-term assets ($3.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZTEK's short-term assets ($3.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZTEK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
-$15.6k
Financing
-$108.6k
ZTEK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZTEK vs Medical Stocks
Zentek Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.